BidaskClub Lowers Aclaris Therapeutics (ACRS) to Strong Sell

Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research downgraded Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Three research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $39.20.

Aclaris Therapeutics (ACRS) traded down $1.13 on Friday, hitting $20.96. The stock had a trading volume of 461,095 shares, compared to its average volume of 298,459. The firm has a market cap of $681.14, a PE ratio of -9.70 and a beta of 1.26. Aclaris Therapeutics has a 1-year low of $20.88 and a 1-year high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $2.00 million. research analysts predict that Aclaris Therapeutics will post -2.59 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Aclaris Therapeutics by 14.6% in the 2nd quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock valued at $51,425,000 after purchasing an additional 242,269 shares in the last quarter. Eagle Asset Management Inc. increased its stake in Aclaris Therapeutics by 1.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,380,549 shares of the biotechnology company’s stock valued at $36,446,000 after purchasing an additional 22,576 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Aclaris Therapeutics by 3.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock valued at $23,030,000 after purchasing an additional 29,896 shares in the last quarter. Vanguard Group Inc. increased its stake in Aclaris Therapeutics by 14.2% in the 2nd quarter. Vanguard Group Inc. now owns 812,318 shares of the biotechnology company’s stock valued at $22,029,000 after purchasing an additional 100,799 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its stake in Aclaris Therapeutics by 85.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock valued at $12,076,000 after purchasing an additional 215,201 shares in the last quarter. 92.35% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “BidaskClub Lowers Aclaris Therapeutics (ACRS) to Strong Sell” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/03/bidaskclub-lowers-aclaris-therapeutics-acrs-to-strong-sell.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply